TrumpRx launches to slash drug prices for cash-paying US patients
President Donald Trump has unveiled his TrumpRx website, offering over 40 drugs at steeply discounted prices to cash-paying patients. The…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
US Food and Drug Administration (FDA) Commissioner Marty Makary said the agency would target the mass-marketing of unapproved drugs amid…
-
Rare paediatric disease voucher programme makes long-awaited US return
After a lengthy period in regulatory limbo, the US Food and Drug Administration’s (FDA) rare paediatric disease priority review voucher…
-
Eli Lilly soars past expectations to hit 45% sales growth in 2025
Booming sales for GLP-1RA drugs fuelled a 45% surge in Eli Lilly’s revenue for 2025, cementing the drugmaker’s dominant position…
-
Novo Nordisk shares tumble 18% after 2026 sales dip warning
Shares in Novo Nordisk have plummeted after the drugmaker forecast a dip in sales and profit growth below analyst expectations…
-
MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4
Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more…
-
Eli Lilly selects Pennsylvania for $3.5bn manufacturing site of obesity drugs
Eli Lilly has chosen Pennsylvania to house a new $3.5bn manufacturing facility that will produce a forthcoming wave of new…
-
FDA’s new scheme to boost US manufacturing commences despite uncertainty
The US Food and Drug Administration (FDA) will start accepting applications for the new PreCheck scheme that will streamline the…
-
AstraZeneca signs $18.5bn weight loss drug deal with CSPC
AstraZeneca has outlaid up to $18.5bn in a licensing deal with China-based CSPC Pharmaceuticals to develop longer lasting weight-loss drugs,…
-
Roche’s 2025 profit blunted by weakened US dollar
Roche’s adjusted operating profit rose by a lower-than-expected 5% in 2025, due to the weakened US dollar, despite the drugmaker…